[EN] 17a-HYDROXYLASE/C17,20-LYASE INHIBITORS<br/>[FR] INHIBITEURS DE LA 17?-HYDROXYLASE/C17,20-LYASE
申请人:NOVARTIS AG
公开号:WO2012035078A1
公开(公告)日:2012-03-22
The present invention provides compounds of Formula (I), or a pharmaceutically acceptable salt thereof, where R1, R2, R3, R4, R5, R6, A and n are as defined herein. A deuteriated derivative of the compound of Formula (I) is also provided.
INHIBITORS OF N-ACYLPHOSPHATIDYLETHANOLAMINE PHOSPHOLIPASE D (NAPE-PLD)
申请人:Universiteit Leiden
公开号:EP3575287A1
公开(公告)日:2019-12-04
The invention relates to a compound of the formula (I) as novel inhibitor of N-acylphosphatidylethanolamine phospholipase D (NAPE-PLD), and to use thereof for the prophylaxis or treatment of diseases associated with NAPE-PLD.
wherein
in a ring A, X1 is N, or CR4; X2 is N or CR5; X3 is N or CH;
with the proviso that at least one of X1 and X3 is N.
[EN] SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF<br/>[FR] MODULATEURS À PETITES MOLÉCULES DE RÉCEPTEURS SIGMA-1 ET SIGMA-2 ET LEURS UTILISATIONS
申请人:UNIV NORTHWESTERN
公开号:WO2020112846A1
公开(公告)日:2020-06-04
This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a tetrahydroindazole structure which function as modulators (e.g., activators or inhibitors) of sigma-1 and/or sigma-2 receptors, and their use as therapeutics for the treatment of cancer and other diseases (e.g., neurological conditions) characterized with sigma-1 and/or sigma-2 receptor activity.
The present invention is directed to a compound of formula (I), or a pharmaceutically acceptable salt, solvate hydrate or stereoisomer thereof, which is useful in treating or preventing disorders mediated by a peroxisome proliferator activated receptor (PPAR) such as syndrome X, type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, arteriosclerosis, and other disorders related to syndrome X and cardiovascular diseases.
C(sp3)-H aminations of N-aroyloxyurea through intermediate iron nitrene species provide chiral 2-imidazolidinones in up to 99% yield and with up to 95% ee (40 examples). This is a rare example in which sustainable iron catalysis is combined with C(sp3)-H amination and asymmetric catalysis. Chiral 2-imidazolidinones are prevalent structural motifs in bioactive molecules and can also be hydrolyzed to valuable